Growth Metrics

Solid Biosciences (SLDB) Capital Expenditures (2017 - 2026)

Quarterly results put Capital Expenditures at $25000.0 for Q1 2026, down 68.75% from a year ago — trailing twelve months through Mar 2026 was -$9000.0 (up 86.96% YoY), and the annual figure for FY2025 was $46000.0, changed.

Solid Biosciences has reported Capital Expenditures over the past 10 years, most recently at $25000.0 for Q1 2026.

  • Capital Expenditures reached $25000.0 in Q1 2026 per SLDB's latest filing, up from -$283000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.5 million in Q4 2023 and bottomed at -$383000.0 in Q3 2022.
  • Median Capital Expenditures over the past 5 years was $25000.0 (2026), compared with a mean of $124294.1.
  • The largest annual shift saw Capital Expenditures soared 2700.0% in 2022 before it tumbled 1187.5% in 2025.
  • Over 5 years, Capital Expenditures stood at $310000.0 in 2022, then soared by 388.71% to $1.5 million in 2023, then tumbled by 102.38% to -$36000.0 in 2024, then tumbled by 686.11% to -$283000.0 in 2025, then skyrocketed by 108.83% to $25000.0 in 2026.
  • Business Quant data shows Capital Expenditures for SLDB at $25000.0 in Q1 2026, -$283000.0 in Q4 2025, and -$174000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 133.40 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 230.60 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 21.83 Mn
10 Solid Biosciences 713.77 Mn 333.09 Mn - 25,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 25,000.00
Mar 31, 2026 25,000.00
Dec 31, 2025 -283,000.00
Dec 31, 2025 -283,000.00
Sep 30, 2025 -174,000.00
Sep 30, 2025 -174,000.00
Jun 30, 2025 423,000.00
Jun 30, 2025 423,000.00
Mar 31, 2025 80,000.00
Mar 31, 2025 80,000.00
Dec 31, 2024 -36,000.00
Dec 31, 2024 -36,000.00
Sep 30, 2024 16,000.00
Sep 30, 2024 16,000.00
Jun 30, 2024 -129,000.00
Jun 30, 2024 -129,000.00
Mar 31, 2024 149,000.00
Mar 31, 2024 149,000.00
Dec 31, 2023 1.52 Mn
Dec 31, 2023 1.52 Mn
Sep 30, 2023 -141,000.00
Sep 30, 2023 -141,000.00
Jun 30, 2023 -365,000.00
Jun 30, 2023 -365,000.00
Mar 31, 2023 506,000.00
Mar 31, 2023 506,000.00
Dec 31, 2022 310,000.00
Dec 31, 2022 310,000.00
Sep 30, 2022 -383,000.00
Sep 30, 2022 -383,000.00
Jun 30, 2022 336,000.00
Jun 30, 2022 336,000.00
Mar 31, 2022 264,000.00
Mar 31, 2022 264,000.00
Dec 31, 2021 -517,000.00
Dec 31, 2021 -517,000.00
Sep 30, 2021 574,000.00
Sep 30, 2021 574,000.00
Jun 30, 2021 12,000.00
Jun 30, 2021 12,000.00
Mar 31, 2021 35,000.00
Mar 31, 2021 35,000.00
Dec 31, 2020 60,000.00
Dec 31, 2020 60,000.00
Sep 30, 2020 80,000.00
Sep 30, 2020 80,000.00
Jun 30, 2020 704,000.00
Jun 30, 2020 704,000.00
Mar 31, 2020 55,000.00
Mar 31, 2020 55,000.00
Dec 31, 2019 645,000.00
Dec 31, 2019 645,000.00
Sep 30, 2019 650,000.00
Sep 30, 2019 650,000.00
Jun 30, 2019 1.14 Mn
Jun 30, 2019 1.14 Mn
Mar 31, 2019 1.95 Mn
Mar 31, 2019 1.95 Mn
Dec 31, 2018 439,000.00
Dec 31, 2018 439,000.00
Sep 30, 2018 -3.70 Mn
Sep 30, 2018 -3.70 Mn
Jun 30, 2018 3.22 Mn
Jun 30, 2018 3.22 Mn
Mar 31, 2018 1.00 Mn
Mar 31, 2018 1.00 Mn
Dec 31, 2017 -1.69 Mn
Dec 31, 2017 -1.69 Mn
Sep 30, 2017 1.63 Mn
Sep 30, 2017 1.63 Mn
Jun 30, 2017 303,000.00
Jun 30, 2017 303,000.00
Mar 31, 2017 16,000.00
Mar 31, 2017 16,000.00